Recently, the understanding of the genetic basis of conotruncal cardiac malformations has undergone significant advances. Conotruncal cardiac malformation such as interruption of the aortic arch (type B), truncus arteriosus, and tetralogy of Fallot (TOF) may be part of a developmental field defect with varying clinical manifestations and are common in DiGeorge (DG), 1 velocardiofacial (VCF), 2 and conotruncal anomaly face syndromes (CTAF). 3 Most patients with DG, VCF, and CTAF syndromes have a chromosomal deletion within band 22q11.2 that can be demonstrated by high-resolution G-banding or fluorescence in situ hybridization (FISH). 4 -7 The clinical expression of this microdeletion can be highly variable between individual patients, 8, 9 within families, 10 -12 and even between monozygotic twins. [13] [14] [15] The phenotype associated with 22q11.2 microdeletions may be subtle and difficult to detect, particularly in the neonatal period. 22q11.2 microdeletions have been reported in nonsyndromic patients with isolated conotruncal cardiac malformations, 16, 17 and occasionally, the noncardiac 22q11.2 phenotype of patients with TOF is not detected until after the molecular diagnosis has been made. 18 Of the conotruncal malformations, TOF is by far the most common, occurring in roughly one in 3000 live births. 19 Truncus arteriosus and interruption of the aortic arch (type B) occur in 1:18,000 and 1:30,000 births, respectively. 19 The detection of a microdeletion within 22q11.2 in a patient with TOF provides very useful information to the clinician. The newborn with a 22q11.2 microdeletion is potentially immunodeficient and at risk for hypocalcemia. Recent surveys suggest that renal and skeletal abnormalities may also be more common than previously suspected. 8 These children may also benefit from further evaluation and early intervention for speech and other developmental delays. The detection of the 22q11.2 microdeletion in an adult patient with TOF also provides useful information for genetic counseling.
METHODS
In a previous study, 20 we evaluated the very long-term follow-up after correction of TOF at the University of Minnesota. In that project, we evaluated the 288 patients who were discharged after a corrective operation between 1954 and 1974. None of these individuals had tetralogy of Fallot with pulmonary atresia (TOF/PA). All individuals in this group are at least of child-bearing age, and several have had grandchildren.. No patients in this population were known to have DG, VCF, or CTAF syndromes.
All available pedigrees were reviewed and classified by the cardiac malformations in the extended family. If multiple family members were affected, the pedigree was classified by the most severe malformation in the nearest relative. As these records included evaluations of children from more than 40 years ago, a diagnosis more specific than "blue baby" (dying in infancy) was unavailable in 4 families. As most patients had left the Minneapolis/St. Paul metropolitan area in the decades after their operation, a systematic evaluation of their noncardiac phenotype was not possible.
Those long-term survivors of TOF correction with an affected first-degree relative, or with extended family members with TOF were invited to participate. Three long-term postoperative survivors were excluded from participation. One individual adopted in infancy and unaware of their adoption and family history was excluded. Two patients in whom their immediate family members' cardiac malformation was limited to aortic valve disease were also excluded, as aortic stenosis re-lated to a bicuspid aortic valve was not believed to be a finding specific of a 22q11.2 microdeletion.
Four postoperative patients with affected family members were excluded as they and their affected family members had died during the follow-up period. Affected adult offspring of deceased patients were invited if they had been patients at the University of Minnesota. One affected child of a deceased index patient was excluded, as he was Ͻ 18 years of age. After these exclusion criteria were applied, 24 long-term survivors and two affected offspring were eligible for study.
This project was evaluated and approved by the Human Subjects Committee of the University of Minnesota's Institutional Review Board. Informed consent was obtained from all participants.
Peripheral blood lymphocytes from study participants were stimulated with phytohemagglutinin and cultured under routine conditions for cytogenetic analysis. Metaphase cells were harvested and prepared onto glass slides. FISH was performed with DNA probes TUPLE1 (VYSIS) and N25 (ONC0R), mapped to 22q11.2 and a control probe (ARSA), which mapped to 22q13.3. FISH was performed according to manufacturer's instructions.
For each study participant, 20 metaphase cells were examined by FISH. Ten cells were examined with TUPLE1, and 10 with N25. Only cells in which the control probe localized to both copies of chromosome 22 were used for scoring. A patient was considered deleted if, in all cells examined, one chromosome #22 hybridized to all probes being evaluated and the other #22 showed hybridization to ARSA but not to TUPLE1 or N25.
RESULTS
These 288 patients have had 242 children, of which 10 (4.2%) have a cardiac malformation (TOF, 4; ventricular septal defect [VSD], 4; double outlet right ventricle, 1; atrial septal defect, 1). This incidence is consistent with previously reported recurrence rates. [3] [4] [5] None of these patients' 33 grandchildren have a cardiac malformation.
Of the 288 postoperative survivors, 30 (10.4%) had at least one first-degree relative with a congenital cardiac malformation (TOF, 11; VSD, 10; aortic stenosis, 2; atrioventricular canal [AVC], 2; partial anomalous pulmonary venous return [PAPVR], 1; "blue baby," 4). Three other patients have a second-or third-degree relative with TOF.
Seventeen long-term survivors of TOF repair and the affected offspring of one deceased patient participated in this study. The cardiac malformation in the nearest relative and results of FISH analysis are shown in Table 1 . One of the 18 patients (5.6%) had a deletion encompassing both TUPLE1 and N25 in all 20 cells examined. She has had one miscarriage and her only living child has TOF and trisomy 21. The family declined to have this child tested for the 22q11.2 microdeletion.
No deletions of TUPLE1 or N25 were detected in the remaining 17 patients who participated in this project. Results with TUPLE1 were the same as those with N25 in all patients.
DISCUSSION
In the literature regarding 22q11.2 microdeletions in TOF, the cardiac and extracardiac phenotypes have been used inconsistently to differentiate between groups more or less likely to carry this microdeletion. If all types of TOF are included, the incidence of microdeletions varies between 8.0% and 26.5%. 17, 18, [21] [22] [23] [24] When patients with pulmonary atresia or absent pulmonary valve syndrome are excluded, the incidence varies between 4.3% and 21.2%. 17, 18, [22] [23] [24] In these reports, most patients were evaluated in infancy or early childhood.
Our patient population differs from these reports not only in their age at evaluation, but also in that they have the potential selection bias of having affected family members, presumably increasing the likelihood of a heritable cause for their congenital heart disease. Although a higher incidence of 22q11.2 microdeletions might have been suspected in this population of patients with TOF and familial congenital heart disease, this was not the case. This lower incidence of the 22q11.2 microdeletion in our population may reflect a true difference in the In an article by Rhoden et al., 25 T-cell deficiencies were much more common in nonsurvivors than survivors of surgery for conotruncal cardiac defects. Sullivan et al. have reported that the immune deficiencies seen in patients with the 22q11.2 microdeletion do not correlate with the clinical phenotype and are not limited to those individuals with DG. 26 If patients with a deletion in the 22q11.2 locus correlate to the subset of patients with T-cell abnormalities, it is possible that these patients would be underrepresented in a population of adult survivors of corrective operations for TOF.
The lower incidence of 22q11.2 microdeletions in our population may reflect an increased severity of cardiac lesions in tetralogy of Fallot in the context of a 22q11.2 microdeletion. With abnormal development of pulmonary arteries, significant segments of the pulmonary vascular bed may be supplied by major aortopulmonary collaterals, complicating the operative correction and increasing the incidence of peripheral pulmonic stenosis. The frequency of major aortopulmonary collateral arteries is higher in TOF/PA in the context of the 22q11.2 microdeletion 24, 27 and may also be more common in TOF without pulmonary atresia in the context of the 22q11.2 microdeletion. 28 Other complicating cardiac malformations may also be present in this setting. 29 In a study of familial conotruncal defects, Wilson et al. 30 found a microdeletion at 22q11.2 in the five families studied, all of which had at least one member with TOF or TOF/PA. However, in a study of familial nonsyndromic conotruncal defects by Debrus et al., 31 TOF was present in 13 of 16 families studied. None of these individuals in Debrus' report were found to have a microdeletion at the 22q11.2 locus by FISH analysis. Digilio et al. 32 found that 10.3% of patients with TOF who did not carry the 22q11.2 microdeletion had first-degree relatives with congenital heart disease, a figure almost identical to our findings. From our report and those of Debrus et al. and of Digilio et al., it is clear that there are many instances of familial tetralogy of Fallot in which the 22q11.2 microdeletions encompassing N25 and or TUPLE1 is not the mechanism of inheritance. One possibility that cannot be excluded in the present study is the existence of loci within 22q11.2 other than D22S75 and TUPLE1 that can influence the development of the relevant cardiac malformations. Recent case reports by Rauch et al. 33 and Saittaa et al. 34 suggest that the existence of such loci distal to TUPLE1 (and outside the commonly deleted region in DG and VCF syndromes) cannot be excluded.
The incidence of cardiac malformations in the offspring of our group of long-term survivors after a corrective operation for TOF is not significantly different than in previous reports. 35 Our data do not suggest that operative correction has allowed a significantly greater portion of patients with TOF and a 22q11.2 microdeletions involving TUPLE1 or N25 to reach child-bearing age.
CONCLUSION
The incidence a 22q11.2 microdeletion appears to be lower in long-term operative survivors than in infants and children with tetralogy of Fallot. The incidence of a 22q11.2 microdeletion may be lower in adult patients after correction of TOF due to attrition related to both the extracardiac and cardiac effects of this microdeletion. Although the incidence of a deletion as detected by current FISH technology is lower in long-term operative survivors, the presence of this deletion has significant implications for both clinical management and genetic counseling. Screening for a 22q11.2 microdeletion should be considered in adult patients after operative correction of TOF, particularly in the setting of familial congenital cardiac malformations. The absence of this microdeletion does not exclude the possibility that the offspring of adult patients with TOF will have a congenital cardiac malformation.
